This product is a recombinant Human antibody that recognizes AGR2. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.
Figure 1 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in DB
Dot Blot analysis of TAB-0708CLV was performed by coating with human AGR2 protein (His tag).
TAB-0708CLV incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 2 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in WB
Western blot analysis of TAB-0708CLV was performed by loading human AGR2 protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-0708CLV and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 3 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in ELISA
ELISA analysis of TAB-0708CLV was performed by coating with human AGR2 protein (His tag). Then blocked with BSA and incubated with TAB-0708CLV. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in DB
Dot Blot analysis of TAB-0708CLV was performed by coating with mouse AGR2 protein (His tag).
TAB-0708CLV incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 5 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in WB
Western blot analysis of TAB-0708CLV was performed by loading mouse AGR2 protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-0708CLV and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 6 Anti-AGR2 Recombinant Antibody (TAB-0708CLV) in ELISA
ELISA analysis of TAB-0708CLV was performed by coating with mouse AGR2 protein (His tag). Then blocked with BSA and incubated with TAB-0708CLV. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-130-VHH | Recombinant Anti-Human AGR2 VHH Single Domain Antibody | IHC, IP, FC, Neut, FUNC | Llama VHH |
There are currently no Customer reviews or questions for TAB-0708CLV. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.